Clinical Trial Update: Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating osimertinib plus bevacizumab and chemotherapy for EGFR+ advanced non-small cell lung cancer with concurrent mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• Osimertinib (osimertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN